GlassScriptPhysician profile
Michael J Mulvaney
NPI 1063405025
$1,290.57
in general payments reported to CMS, 2019-2025
14 companies · $443 in 2025
The $443 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $216 · 2022: $62.48 · 2023: $181 · 2024: $388 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $224.41 | 2022-2025 | |
| Abbvie INC. | $213.40 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $206.91 | 2021-2024 | Dupixent, Libtayo |
| Incyte Corporation | $129.05 | 2024-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $106.61 | 2021 | |
| Janssen Biotech, INC. | $101.89 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $70.83 | 2023-2025 | Taltz, Ebglyss |
| Amgen INC. | $51.83 | 2024 | Otezla |
| Ucb, INC. | $47.70 | 2023-2024 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $43.78 | 2023-2024 | Ilumya |
| Genzyme Corporation | $35.16 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $22.10 | 2025 | Acthar |
| Leo Pharma INC. | $19.34 | 2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $17.56 | 2025 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mulvaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.